+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Glioblastoma Multiforme Treatment Market by Treatment Type (Drug Therapy, Radiotherapy, Supportive Care), Drug Class (Alkylating Agents, Checkpoint Inhibitors, Monoclonal Antibodies), Line Of Therapy, End User, Distribution Channel - Global Forecast 2025-2030- Product Image
Glioblastoma Multiforme Treatment Market by Treatment Type (Drug Therapy, Radiotherapy, Supportive Care), Drug Class (Alkylating Agents, Checkpoint Inhibitors, Monoclonal Antibodies), Line Of Therapy, End User, Distribution Channel - Global Forecast 2025-2030- Product Image
Sale

Glioblastoma Multiforme Treatment Market by Treatment Type (Drug Therapy, Radiotherapy, Supportive Care), Drug Class (Alkylating Agents, Checkpoint Inhibitors, Monoclonal Antibodies), Line Of Therapy, End User, Distribution Channel - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 189 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5888133
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Glioblastoma Multiforme Treatment Market is evolving rapidly as clinical innovation and operational challenges align to reshape care pathways and investment opportunities. Senior decision-makers must anticipate transformative trends and adapt strategies amid complex therapeutic and supply chain dynamics to maintain market leadership.

Market Snapshot: Glioblastoma Multiforme Treatment Market Trends

The Glioblastoma Multiforme Treatment Market grew from USD 3.36 billion in 2024 to USD 3.65 billion in 2025. It is projected to reach USD 5.39 billion by 2030, driven by a CAGR of 8.17%. Robust market growth is supported by new therapeutic modalities, an expanding focus on patient-centered treatment strategies, and strategic collaborations among leading biopharmaceutical players. Heightened interest from value-based payers and regional investments is accelerating the deployment of innovative therapies across primary and specialty care settings.

Scope & Segmentation: Comprehensive Coverage of the Glioblastoma Multiforme Treatment Market

This report delivers actionable insights by segmenting the glioblastoma multiforme treatment landscape across key categories, technologies, and regions:

  • Treatment Types: Drug therapies, including chemotherapy, gene therapy, immunotherapy, and targeted therapy; radiotherapy techniques such as brachytherapy, external beam, and radiosurgery; supportive care; surgical approaches including biopsy and craniotomy.
  • Drug Classes: Alkylating agents, checkpoint inhibitors, monoclonal antibodies, oncolytic virus therapies, and vaccine therapies.
  • Line of Therapy: Protocols covering first, second, and third line treatments.
  • End Users: Hospitals, specialty clinics, research institutes, and home healthcare providers.
  • Distribution Channels: Hospital pharmacies, retail pharmacies, and online pharmacies.
  • Regional Segments: Americas (United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East and Africa (including United Kingdom, Germany, France, key Nordic and Middle Eastern markets), and Asia-Pacific (China, India, Japan, Australia, Southeast Asian and Pacific nations).
  • Company Developments: Competitive strategies from global leaders such as F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Novocure Ltd., Teva Pharmaceutical Industries Limited, and others.

Key Takeaways for Senior Decision Makers

  • Therapeutic innovation is shifting toward precision medicine, with increased integration of molecular profiling and targeted agents enabling more personalized treatment planning.
  • Multidisciplinary approaches unite neurosurgery, radiotherapy, and evolving systemic treatments, fostering the convergence of clinical specialties.
  • Supply chain and procurement strategies are being optimized in response to external economic and regulatory factors, resulting in greater localization of manufacturing and agile vendor networks.
  • Real-world evidence generation is becoming central to demonstrating value and driving adoption, supplementing clinical trial data with outcome-based assessments.
  • Corporate collaborations, including academic partnerships and contract research arrangements, are accelerating new product development and facilitating regulatory navigation.
  • Digital health and telemedicine platforms are expanding care reach, supporting patient management in both advanced and resource-constrained markets.

Tariff Impact: Navigating New United States Tariffs in 2025

The implementation of new United States tariffs in 2025 is reshaping global glioblastoma treatment supply chains by increasing duties on vital pharmaceutical ingredients and equipment. Manufacturers are responding with shifts toward regional procurement and local production hubs to manage increased costs and maintain continuity. Stakeholders are integrating tariff contingencies in budgeting and renegotiating supplier contracts, underscoring the need for flexible and resilient supply chain frameworks to preserve clinical trial continuity and ensure product availability.

Methodology & Data Sources

The research employs rigorous methods, combining comprehensive secondary data from peer-reviewed journals, regulatory bodies, and company disclosures with primary interviews and surveys involving oncology, pharmacoeconomics, and supply chain specialists. Segmentation analysis, scenario modeling for tariff impacts, and triangulation across sources ensure data reliability and contextual insight for strategic decision-making.

Why This Report Matters

  • Enables strategic resource allocation by highlighting emerging therapeutic trends and regional growth opportunities in the glioblastoma multiforme treatment market.
  • Provides benchmarking tools for evaluating the impact of policy changes and competitive dynamics on product positioning and value-based negotiation.
  • Equips leaders with critical insights to optimize development partnerships, mitigate market entry risks, and expand patient access in both mature and emerging markets.

Conclusion

The glioblastoma multiforme treatment landscape is marked by scientific advancement, operational complexity, and the necessity for tailored segment strategies. Stakeholders equipped with robust commercial and clinical intelligence will be better positioned to navigate evolving treatment paradigms and partner ecosystems.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Integration of tumor-treating fields with personalized CAR T-cell therapies to improve glioblastoma patient outcomes
5.2. Emergence of bispecific antibodies targeting EGFRvIII and PD-1 pathways in glioblastoma immunotherapy
5.3. Development of convection-enhanced delivery systems for precision drug transport across the blood brain barrier
5.4. Adoption of liquid biopsy techniques for real-time monitoring of glioblastoma treatment response and resistance
5.5. Rising investment in oncolytic virus therapies engineered to selectively target glioblastoma stem cell populations
5.6. Clinical advancement of tumor microenvironment modulators to overcome immunosuppressive niches in glioblastoma treatment
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Glioblastoma Multiforme Treatment Market, by Treatment Type
8.1. Introduction
8.2. Drug Therapy
8.2.1. Chemotherapy
8.2.1.1. Carmustine
8.2.1.2. Combination Chemotherapy
8.2.1.3. Temozolomide
8.2.2. Gene Therapy
8.2.2.1. Gene Editing
8.2.2.2. Oncolytic Virus Therapy
8.2.3. Immunotherapy
8.2.3.1. Checkpoint Inhibitors
8.2.3.2. Vaccines
8.2.4. Targeted Therapy
8.2.4.1. Bevacizumab
8.2.4.2. EGFR Inhibitors
8.3. Radiotherapy
8.3.1. Brachytherapy
8.3.2. External Beam Radiotherapy
8.3.3. Radiosurgery
8.4. Supportive Care
8.4.1. Antiepileptic Drugs
8.4.2. Corticosteroids
8.5. Surgical
8.5.1. Biopsy Procedures
8.5.2. Craniotomy
9. Glioblastoma Multiforme Treatment Market, by Drug Class
9.1. Introduction
9.2. Alkylating Agents
9.2.1. Carmustine
9.2.2. Temozolomide
9.3. Checkpoint Inhibitors
9.3.1. Nivolumab
9.3.2. Pembrolizumab
9.4. Monoclonal Antibodies
9.4.1. Bevacizumab
9.5. Oncolytic Virus Therapies
9.5.1. Sitimogene Ceradenovac
9.6. Vaccine Therapies
9.6.1. Dendritic Cell Vaccines
9.6.2. Peptide Vaccines
10. Glioblastoma Multiforme Treatment Market, by Line Of Therapy
10.1. Introduction
10.2. First Line
10.3. Second Line
10.4. Third Line
11. Glioblastoma Multiforme Treatment Market, by End User
11.1. Introduction
11.2. Home Healthcare
11.3. Hospitals
11.4. Research Institutes
11.5. Specialty Clinics
12. Glioblastoma Multiforme Treatment Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacy
12.3. Online Pharmacy
12.4. Retail Pharmacy
13. Americas Glioblastoma Multiforme Treatment Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Glioblastoma Multiforme Treatment Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Glioblastoma Multiforme Treatment Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. F. Hoffmann-La Roche Ltd
16.3.2. Merck & Co., Inc.
16.3.3. Novocure Ltd.
16.3.4. Teva Pharmaceutical Industries Limited
16.3.5. Viatris Inc.
16.3.6. Sandoz International GmbH
16.3.7. Dr. Reddy’s Laboratories Limited
16.3.8. Accord Healthcare Limited
16.3.9. Zydus Lifesciences Limited
16.3.10. Sun Pharmaceutical Industries Limited
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. GLIOBLASTOMA MULTIFORME TREATMENT MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2030 (%)
FIGURE 10. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. GLIOBLASTOMA MULTIFORME TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. GLIOBLASTOMA MULTIFORME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. GLIOBLASTOMA MULTIFORME TREATMENT MARKET: RESEARCHAI
FIGURE 26. GLIOBLASTOMA MULTIFORME TREATMENT MARKET: RESEARCHSTATISTICS
FIGURE 27. GLIOBLASTOMA MULTIFORME TREATMENT MARKET: RESEARCHCONTACTS
FIGURE 28. GLIOBLASTOMA MULTIFORME TREATMENT MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. GLIOBLASTOMA MULTIFORME TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CARMUSTINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CARMUSTINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COMBINATION CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COMBINATION CHEMOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TEMOZOLOMIDE, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TEMOZOLOMIDE, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE EDITING, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE EDITING, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE THERAPY, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY EGFR INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY EGFR INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG THERAPY, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY BRACHYTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY BRACHYTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY EXTERNAL BEAM RADIOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY EXTERNAL BEAM RADIOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOSURGERY, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOSURGERY, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ANTIEPILEPTIC DRUGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ANTIEPILEPTIC DRUGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SURGICAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SURGICAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY BIOPSY PROCEDURES, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY BIOPSY PROCEDURES, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CRANIOTOMY, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CRANIOTOMY, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SURGICAL, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SURGICAL, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CARMUSTINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CARMUSTINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TEMOZOLOMIDE, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TEMOZOLOMIDE, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY NIVOLUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY NIVOLUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ONCOLYTIC VIRUS THERAPIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ONCOLYTIC VIRUS THERAPIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SITIMOGENE CERADENOVAC, BY REGION, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SITIMOGENE CERADENOVAC, BY REGION, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ONCOLYTIC VIRUS THERAPIES, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ONCOLYTIC VIRUS THERAPIES, 2025-2030 (USD MILLION)
TABLE 105. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINE THERAPIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 106. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINE THERAPIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 107. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DENDRITIC CELL VACCINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 108. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DENDRITIC CELL VACCINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 109. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY PEPTIDE VACCINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 110. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY PEPTIDE VACCINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 111. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINE THERAPIES, 2018-2024 (USD MILLION)
TABLE 112. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINE THERAPIES, 2025-2030 (USD MILLION)
TABLE 113. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 114. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 115. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 116. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 117. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 118. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 119. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 120. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY THIRD LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 121. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 122. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 123. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 124. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 125. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 126. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 127. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
TABLE 128. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
TABLE 129. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 130. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 131. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 132. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 133. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 134. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 135. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 136. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 137. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 138. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 139. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 140. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 141. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2024 (USD MILLION)
TABLE 142. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG THERAPY, 2025-2030 (USD MILLION)
TABLE 143. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 144. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 145. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
TABLE 146. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE THERAPY, 2025-2030 (USD MILLION)
TABLE 147. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 148. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 149. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 150. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 151. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2024 (USD MILLION)
TABLE 152. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2025-2030 (USD MILLION)
TABLE 153. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2024 (USD MILLION)
TABLE 154. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2025-2030 (USD MILLION)
TABLE 155. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SURGICAL, 2018-2024 (USD MILLION)
TABLE 156. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SURGICAL, 2025-2030 (USD MILLION)
TABLE 157. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 158. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 159. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2024 (USD MILLION)
TABLE 160. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2025-2030 (USD MILLION)
TABLE 161. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 162. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 163. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 164. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 165. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ONCOLYTIC VIRUS THERAPIES, 2018-2024 (USD MILLION)
TABLE 166. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ONCOLYTIC VIRUS THERAPIES, 2025-2030 (USD MILLION)
TABLE 167. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINE THERAPIES, 2018-2024 (USD MILLION)
TABLE 168. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINE THERAPIES, 2025-2030 (USD MILLION)
TABLE 169. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 170. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 171. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 172. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 173. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 174. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 175. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 176. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 177. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 178. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 179. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2024 (USD MILLION)
TABLE 180. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG THERAPY, 2025-2030 (USD MILLION)
TABLE 181. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 182. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 183. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
TABLE 184. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE THERAPY, 2025-2030 (USD MILLION)
TABLE 185. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 186. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 187. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 188. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 189. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2024 (USD MILLION)
TABLE 190. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2025-2030 (USD MILLION)
TABLE 191. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2024 (USD MILLION)
TABLE 192. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2025-2030 (USD MILLION)
TABLE 193. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SURGICAL, 2018-2024 (USD MILLION)
TABLE 194. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SURGICAL, 2025-2030 (USD MILLION)
TABLE 195. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 196. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 197. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2024 (USD MILLION)
TABLE 198. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2025-2030 (USD MILLION)
TABLE 199. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 200. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 201. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 202. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 203. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ONCOLYTIC VIRUS THERAPIES, 2018-2024 (USD MILLION)
TABLE 204. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ONCOLYTIC VIRUS THERAPIES, 2025-2030 (USD MILLION)
TABLE 205. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINE THERAPIES, 2018-2024 (USD MILLION)
TABLE 206. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINE THERAPIES, 2025-2030 (USD MILLION)
TABLE 207. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 208. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 209. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 210. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 211. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 212. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 213. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 214. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 215. CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 216. CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 217. CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2024 (USD MILLION)
TABLE 218. CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG THERAPY, 2025-2030 (USD MILLION)
TABLE 219. CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 220. CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 221. CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
TABLE 222. CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE THERAPY, 2025-2030 (USD MILLION)
TABLE 223. CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 224. CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 225. CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 226. CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 227. CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2024 (USD MILLION)
TABLE 228. CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2025-2030 (USD MILLION)
TABLE 229. CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2024 (USD MILLION)
TABLE 230. CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2025-2030 (USD MILLION)
TABLE 231. CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SURGICAL, 2018-2024 (USD MILLION)
TABLE 232. CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SURGICAL, 2025-2030 (USD MILLION)
TABLE 233. CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 234. CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 235. CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2024 (USD MILLION)
TABLE 236. CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2025-2030 (USD MILLION)
TABLE 237. CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 238. CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 239. CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 240. CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 241. CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ONCOLYTIC VIRUS THERAPIES, 2018-2024 (USD MILLION)
TABLE 242. CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ONCOLYTIC VIRUS THERAPIES, 2025-2030 (USD MILLION)
TABLE 243. CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINE THERAPIES, 2018-2024 (USD MILLION)
TABLE 244. CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINE THERAPIES, 2025-2030 (USD MILLION)
TABLE 245. CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 246. CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 247. CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 248. CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 249. CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 250. CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 251. MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 252. MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 253. MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2024 (USD MILLION)
TABLE 254. MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG THERAPY, 2025-2030 (USD MILLION)
TABLE 255. MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 256. MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 257. MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
TABLE 258. MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE THERAPY, 2025-2030 (USD MILLION)
TABLE 259. MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 260. MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 261. MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 262. MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 263. MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2024 (USD MILLION)
TABLE 264. MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2025-2030 (USD MILLION)
TABLE 265. MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2024 (USD MILLION)
TABLE 266. MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2025-2030 (USD MILLION)
TABLE 267. MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SURGICAL, 2018-2024 (USD MILLION)
TABLE 268. MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SURGICAL, 2025-2030 (USD MILLION)
TABLE 269. MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 270. MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 271. MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2024 (USD MILLION)
TABLE 272. MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2025-2030 (USD MILLION)
TABLE 273. MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 274. MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 275. MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 276. MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 277. MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ONCOLYTIC VIRUS THERAPIES, 2018-2024 (USD MILLION)
TABLE 278. MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ONCOLYTIC VIRUS THERAPIES, 2025-2030 (USD MILLION)
TABLE 279. MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINE THERAPIES, 2018-2024 (USD MILLION)
TABLE 280. MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINE THERAPIES, 2025-2030 (USD MILLION)
TABLE 281. MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 282. MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 283. MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 284. MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 285. MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 286. MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 287. BRAZIL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 288. BRAZIL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 289. BRAZIL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2024 (USD MILLION)
TABLE 290. BRAZIL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG THERAPY, 2025-2030 (USD MILLION)
TABLE 291. BRAZIL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 29

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Glioblastoma Multiforme Treatment market report include:
  • F. Hoffmann-La Roche Ltd
  • Merck & Co., Inc.
  • Novocure Ltd.
  • Teva Pharmaceutical Industries Limited
  • Viatris Inc.
  • Sandoz International GmbH
  • Dr. Reddy’s Laboratories Limited
  • Accord Healthcare Limited
  • Zydus Lifesciences Limited
  • Sun Pharmaceutical Industries Limited

Table Information

Report AttributeDetails
No. of Pages189
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 3.65 Billion
Forecasted Market Value ( USD ) by 2030 $ 5.39 Billion
Compound Annual Growth Rate8.1%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Glioblastoma Multiforme (GBM) Treatment Market Report 2025 - Product Image

Glioblastoma Multiforme (GBM) Treatment Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Glioblastoma Multiforme Treatment (GBM) - Global Strategic Business Report - Product Image

Glioblastoma Multiforme Treatment (GBM) - Global Strategic Business Report

  • Report
  • 192 Pages
  • Global
From
Glioblastoma Multiforme Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Glioblastoma Multiforme Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Glioblastoma Multiforme (GBM) - Pipeline Insight, 2025 - Product Image

Glioblastoma Multiforme (GBM) - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Glioblastoma Multiforme Treatment Market 2024-2028 - Product Image

Glioblastoma Multiforme Treatment Market 2024-2028

  • Report
  • 137 Pages
  • Global
From

About the Glioblastoma Drug Market

The Glioblastoma Drug market is a subset of the larger Brain Cancer Drug market. It is composed of drugs used to treat glioblastoma, a type of brain cancer. These drugs are typically used in combination with surgery, radiation, and chemotherapy to treat the disease. Common drugs used to treat glioblastoma include temozolomide, bevacizumab, and lomustine. These drugs are used to reduce tumor size, slow tumor growth, and reduce symptoms. The Glioblastoma Drug market is highly competitive, with many companies vying for market share. Some of the major players in the market include Novartis, Merck, Roche, Pfizer, and Bristol-Myers Squibb. Other companies in the market include Celgene, AstraZeneca, and Eli Lilly. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.